Follow-up of treatment of anti-tumor necrosis factor alpha blocker in 35 patients with refractory SAPHO syndrome

doi:10.3969/j.issn.1004-583X.2016.01.011

Abstract

Abstract: Objective To investigate the efficacy and safety of anti-tumor necrosis factor alpha (TNF-α) antagonist in the treatment of refractory SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis and osteitis).Methods A total of 35 patients with refractory SAPHO syndrome treated by TNF-α antagonist was retrospectively studied and the response of patients was recorded.Results The treatment time for 35 patients with TNF-α antagonist was 2 weeks to 240 weeks, and the average time was (24.4±48.8) weeks. The ostalgia in 32 cases (91.4%) significantly improved in the early time: the ostalgia in 22 cases (68.8%) has been improved after receiving once therapy; the ostalgia in 8 cases (32.0%) improved after receiving twice therapy; the ostalgia in 2 cases (6.2%) improved after receiving therapy three times. For rash, 15 cases were effective in early stage, but in the maintenance treatment, 6 cases had a relapse or aggravation of skin rash and 12 cases had no improvement. A total of 9 cases had adverse reactions: 6 cases had new rash, 1 case had submaxillaritis, 1 case had buttock abscess and 1 case had pneumonia.Conclusion Among the patients with refractory SAPHO syndrome receiving TNF-α antagonist treatment, 91.4% of patients with ostalgia significantly improved in the early time and the improvement was more effective in the first three therapy; but in the maintenance medication, only 11 cases (31.4%) were effective. The improvement of the rash was not wholly satisfied, only 9 cases (27.2%) were effective and it was possible to induce a new or aggravated rash, and also there was potential risk to be infected.

Key words: acquired hyperostosis syndrome, tumor necrosis factor-alpha, treatment outcome, exanthema

CLC Number:

R681.3

Li Chen, Wang Jing, Shi Xiaohu, Liu Jinhe, Hao Weixin, Dong Zhenhua, Zhang Wen. Follow-up of treatment of anti-tumor necrosis factor alpha blocker in 35 patients with refractory SAPHO syndrome[J]. Clinical Focus, 2016, 31(1): 45-47.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2016.01.011

https://huicui.hebmu.edu.cn/EN/Y2016/V31/I1/45

References

[1] Chamot AM, Benhamou CL, Kahn MF, et al. Acne-pustulosis-hyperostosis-osteitis syndrome. Results of a national survey. 85 cases[J]. Rev Rhum Mal Osteoartic, 1987,54(3):187-196.
[2] Nguyen MT, Borchers A, Selmi C, et al. The SAPHO syndrome[J]. Semin Arthritis Rheum, 2012,42(3):254-265.
[3] Rohekar G,Inman RD. Conundrums in nosology: synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome and spondylarthritis[J]. Arthritis Rheum,2006,55(4):665-669.
[4] Kim C. Current knowledge and future prospects for SAPHO syndrome[J]. Drugs Today (Barc),2014,50(11):757-761.
[5] Oliveri I, Padula A, Palazzi C. Pharmacological management of SAPHO syndrome[J]. Expert Opin Investig Drugs,2006,15(10):1229-1233.
[6] Matzaroglou Ch, Velissaris D, Karageorgos A, et al. SAPHO syndrome diagnosis and treatment: report of five cases and review of the literature[J]. Open Orthop J,2009,3:100-106.
[7] Zhao Z, Li Y, Zhao H, et al. Synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome with review of the relevant published work[J]. J Dermatol,2011,38(2):155-159.
[8] Jung J, Molinger M, Kohn D, et al. Intra-articular glucocorticosteroid injection into sternocostoclavicular joints in patients with SAPHO syndrome[J]. Sci Total Environ,2012, 42(3):266-270.
[9] Hayem G, Bouchaud-Chabot A, Benali K, et al. SAPHO syndrome: a long-term follow-up study of 120 cases[J].Semin Arthritis Rheum,1999,29(3):159-171.
[10] Hayama K, Inadomi T, Fujisawa D, et al. A pilot study of medium-dose cyclosporine for the treatment of palmoplantar pustulosis complicated with pustulotic arthro-osteitis[J]. Eur J Dermatol,2010, 20(6):758-762.
[11] Assmann G, Kueck O, Kirchhoff T, et al. Efficacy of antibiotic therapy for SAPHO syndrome is lost after its discontinuation: an interventional study[J]. Arthritis Res Ther,2009, 11(5): R140.
[12] Wagner AD, Andresen J, Jendro MC, et al. Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome[J]. Arthritis Rheum,2002,46(7):1965-1968.
[13] Massara A, Cavazzini PL, Trotta F. In SAPHO syndrome anti-TNF-alpha therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations[J]. Rheumatology (Oxford),2006,45(6):730-733.
[14] Moll C, Hernández MV, Caete JD, et al. Ilium osteitis as the main manifestation of the SAPHO syndrome: response to infliximab therapy and review of the literature[J].Semin Arthritis Rheum,2008, 37(5):299-306.
[15] Castellví I, Bonet M, Narváez JA,et al. Successful treatment of SAPHO syndrome with adalimumab: a case report[J]. Clin Rheumatol, 2010, 29(10):1205-1207.
[16] Ben Abdelghani K, Dran DG, Gottenberg JE, et al. Tumor necrosis factor-alpha blockers in SAPHO syndrome[J]. J Rheumatol,2010,37(8):1699-1704.
[17] Garcovich S,Amelia R,Magarelli N, et al. Long-term of severe SAPHO sydrome with adalimumab: case report and a review of the literature[J]. Am J Clin Dermatol,2012, 13(1):55-59.
[18] Amital H, Applbaum YH, Aamar S,et al. SAPHO syndrome treated with pamidronate: an open-label study of 10 patients[J]. Rheumatology (Oxford),2004, 43(5): 658-661.
[19] Henriques CC, Sousa M, Panarra A, et al. The dark side of SAPHO syndrome[J]. BMJ Case Rep, 2011, 2011. pii: bcr1120115197.
[20] Wendling D, Prati C, Aubin F. Anakinra treatment of SAPHO syndrome: short-term results of an open study[J]. Ann Rheum, 2012, 71(6): 1098-1100.
[21] Hess S,Hospach T,Nossal R,et al. Life-threateningdisseminatedtuberculosisas acomplicationof TNF-αblockadein anadolescent[J]. Eur J Pediatr,2011, 170(10):1337-1342.